Sotatercept Versus Selexipag in Severe Pulmonary Arterial Hypertension: An Indirect Comparison of Efficacy Based on an Artificial-Intelligence Method That Reconstructed Patient-Level Data From Three R
4 hours ago
- #AI-reconstructed data
- #pulmonary arterial hypertension
- #indirect comparison
- Study compares sotatercept and selexipag for severe pulmonary arterial hypertension (PAH) using AI-reconstructed patient data.
- Indirect comparison based on three randomized trials (STELLAR, GRIPHON, HYPERION) shows sotatercept may be more effective than selexipag.
- AI method (IPDfromKM) used to reconstruct individual patient data from Kaplan-Meier curves.
- Results indicate a hazard ratio (HR) of 0.45 favoring sotatercept over selexipag (95% CI 0.29-0.70; p = 0.00036).
- Placebo arms showed no significant heterogeneity, supporting the validity of the indirect comparison.
- Findings suggest sotatercept reduces PAH-related events more effectively, though based on reconstructed data.